Skip to Main Content

In another setback in the lucrative lung cancer market, Bristol-Myers Squibb (BMY) said Thursday that it is withdrawing its application with the Food and Drug Administration to use its cancer immunotherapy blockbuster, Opdivo, in combination with Yervoy, a second Bristol drug, for some patients with previously untreated non-small cell lung cancer.

The news comes as Bristol is announcing strong fourth-quarter earnings, with sales up 10 percent from last year to $6 billion and earnings per share excluding items of 94 cents, 10 cents ahead of the expectations of analysts polled by FirstCall. Sales of Opdivo increased 33 percent to $1.8 billion in the quarter, helping to drive the strong quarter. The company’s announcement also comes just weeks after it said it would purchase rival cancer drug maker Celgene for $74 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!